|Bid||25.77 x 1300|
|Ask||25.83 x 800|
|Day's Range||25.26 - 25.91|
|52 Week Range||14.81 - 42.17|
|Beta (3Y Monthly)||2.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||41.40|
SOUTH SAN FRANCISCO, Calif. , July 17, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial ...
SOUTH SAN FRANCISCO, Calif., July 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced new in vitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and rivaroxaban and the ability of four-factor prothrombin complex concentrate (4F-PCC) to correct inhibition of thrombin generation, compared with warfarin anticoagulation reversal by 4F-PCC. Results showed that, while effective in reversing inhibition of thrombin generation in plasma from patients treated with warfarin, 4F-PCCs did not appear to have an effect on the inhibition of thrombin generation by apixaban or rivaroxaban unless the Factor Xa inhibitor concentration was less than 75 ng/mL.
SOUTH SAN FRANCISCO, Calif., June 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with relapsed/refractory follicular lymphoma (FL) receiving cerdulatinib alone or in combination with rituximab. Data were presented this month in a poster session at the 24th Congress of the European Hematology Association (EHA) in Amsterdam (June 13-16) and during an oral session today at the 15th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (June 18-22).
Portola Pharmaceuticals Inc NASDAQ/NGS:PTLAView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for PTLA with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PTLA. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PTLA are favorable, with net inflows of $2.34 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SOUTH SAN FRANCISCO, Calif., May 28, 2019 -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer,.
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)European market launchOn April 26, Portola Pharmaceuticals (PTLA) issued a press release announcing conditional marketing authorization granted by the European Commission to
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Reimbursement and accessIn its first quarter earnings conference call, Portola Pharmaceuticals (PTLA) highlighted the stocking of Andexxa by 300 hospitals in the US with a
Portola Pharmaceuticals, Inc.® (PTLA) today announced the presentation of a new analysis of data from an important subgroup of ANNEXA-4, the Company’s Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] in patients with acute major bleeding while taking a Factor Xa inhibitor. Data on a key subset of patients with spontaneous (non-traumatic) intracranial hemorrhage are being featured in an oral presentation today at the 5th European Stroke Organisation Conference (ESOC 2019) in Milan, Italy. Spontaneous intracranial hemorrhage is a bleeding event in the brain not caused by trauma, and it is associated with high rates of mortality and morbidity.
Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 0.00% and 6.38%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.17. Losses, adjusted for non-recurring costs, came to $1.02 per share. The results matched Wall Street expectations. ...
– First Quarter Revenues of $22.2 Million; Andexxa® Product Revenues Grow 45% to $20.3 Million – – European Commission Approval of Ondexxya®; Staged Commercial Launch Planned.
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Portola Pharmaceuticals, Inc. (NASDAQ: PTLA ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 8:30 ...
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost more than 25%. Facebook, which was the second most popular stock, lost 20% amid uncertainty regarding the interest rates and tech […]
Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Portola Pharmaceuticals, Inc.® (PTLA) today announced that the European Commission (EC) has granted conditional Marketing Authorization for Ondexxya™ (andexanet alfa). Ondexxya is the first and only antidote approved in Europe for adult patients treated with the Factor Xa inhibitor apixaban or rivaroxaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Portola Pharmaceuticals, Inc.® (PTLA) today announced that Dr. John Curnutte, M.D., Ph.D., Executive Vice President and Head of Research and Development, will retire on May 17, 2019, after more than eight years of distinguished service. Dr. Curnutte will remain in a consultancy role, providing guidance to Portola’s President and Chief Executive Officer Scott Garland and engaging with key academic and scientific thoughtleaders in the field on the ongoing development of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] and cerdulatinib.
Portola Pharmaceuticals, Inc.® (PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2019, and provide a general business overview on Wednesday, May 8, 2019, at 8:30 a.m. ET (5:30 a.m. PT). Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban or apixaban.